Journey Medical Corporation announced that the FDA has accepted the Company's New Drug Application (NDA) for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the treatment of inflammatory lesions and erythema of rosacea in adults. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of November 4, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.66 USD | -0.35% | +8.64% | -1.74% |
Jul. 11 | Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors | CI |
May. 13 | Transcript : Journey Medical Corporation, Q1 2024 Earnings Call, May 13, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.74% | 113M | |
+62.66% | 854B | |
+40.42% | 636B | |
-4.37% | 361B | |
+17.16% | 324B | |
+9.87% | 301B | |
+15.66% | 247B | |
+4.21% | 230B | |
+17.90% | 228B | |
+14.86% | 177B |
- Stock Market
- Equities
- DERM Stock
- News Journey Medical Corporation
- Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea